FindTrial
Sign In

Randomized controlled clinical trial protocol to control ovarian hyperstimulation (COH) by different trigger methods in different ovarian response populations

Randomized controlled clinical trial protocol to control ovarian hyperstimulation (COH) by different trigger methods in different ovarian response populations - Different trigger methods in different ovarian response populations

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061825
Enrollment
Unknown
Registered
2022-07-03
Start date
2023-07-27
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

Patients with low ovarian response:HCG 2000 IU+GnRH-a 0.2 mg
Patients with low ovarian response:HCG 6000 IU+GnRH-a 0.2 mg
Patients with normal ovarian response:hCG 1000 IU+GnRH-a 0.2 mg
Patients with normal ovarian response:hCG6000IU (Lidepot)+GnRH-a 0.1 mg
Patients with high ovarian response:GnRH-a 0.2 mg
Patients with high ovarian response:hCG 1000 IU+GnRH-a 0.2 mg

Sponsors

Chengdu Xi'nan Gynecology Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Ovarian low response, normal response, high response population according to the Bologna consensus: (1) The minimum criteria required to define POR are the presence of at least two of three characteristics: 1) Older women (40 years or older) or other risk factors for poor response; 2) Three or less oocytes after stimulation in the previous cycle; 3) Low ovarian reserve test (sinus follicle count of 5 to 7 follicles or anti-muslerian hormone (AMH) level of 0.51-1.10 ng/mL); (2) People with normal ovarian response: aged 4.5 ng/ml, AFC >= 20; 2. 18 kg/m2 = 7 cm; 5. Antagonist regimen.

Exclusion criteria

Exclusion criteria: 1. Women with hydrosalpingers, and women with endocrine diseases such as diabetes, hypertension, congenital adrenal hyperplasia, Cushing's syndrome, congenital uterine abnormalities, and repeated implant failure (two transplants); 2. Couples with severe uncontrolled medical or metabolic disorders were also excluded. 3. Patient with an ICSI (intracytoplasmic sperm injection) cycle.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;Excellent embryo rate;MII oocyte rate;Continuing pregnancy rate;Early abortion rate;live birth rate;—

Secondary

MeasureTime frame
Number of oocytes obtained;Incidence of severe ovarian hyperstimulation syndrome (OHSS);Cancel the cycle rate;No embryo availability rate;Ectopic pregnancy rate;—

Countries

China

Contacts

Public ContactQi Wan/Hu Yuling

Chengdu Xi'nan Gynecology Hospital

wanqi123@163.com+86 18280266982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026